Clinical Activity & Immunogenicity of a Neoantigen Immunotherapy in Non-Small Cell Lung Cancer

Time: 4:30 pm
day: Day One

Details:

  • An off-the-shelf, Listeria based-neoantigen immunotherapy (ADXS-503) has been developed using 22 most prevalent tumor associated antigens in NSCLC
  • Dose escalation with monotherapy and in combination with pembrolizumab have been conducted
  • A dose expansion cohort using ADXS-503 as an add-on-therapy to pembrolizumab at progression, has shown potential to reverse resistance to the checkpoint inhibitor

Speakers:

Andres Gutierrez